Brexanolone (Zulresso): Finally, an FDA-Approved Treatment for Postpartum Depression.

To review the safety and efficacy of brexanolone for the treatment of moderate to severe postpartum depression (PPD). A literature search through PubMed was conducted (January 2012 to July 2019) using the keyword for clinical trials published in the English language. Articles were selected if they were related to the Food and Drug Administration (FDA) approval of brexanolone or provided novel clinical information regarding this drug entity.

New and emerging pharmacologic therapies for type 2 diabetes, dyslipidemia, and obesity.

Background: Type 2 diabetes, dyslipidemia, and obesity continue to be common disorders that many clinicians and patients struggle to control. There are likely numerous reasons for poor control of these diseases, including medication efficacy and adverse effects, access to medications and health care, poor adherence, and lack of lifestyle changes by patients. Several new and emerging medications may help resolve these issues.